Purple Biotech Statistics
Total Valuation
Purple Biotech has a market cap or net worth of ILS 21.69 million. The enterprise value is 2.24 million.
| Market Cap | 21.69M |
| Enterprise Value | 2.24M |
Important Dates
The last earnings date was Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Purple Biotech has 1.81 billion shares outstanding. The number of shares has increased by 82.76% in one year.
| Current Share Class | 1.81B |
| Shares Outstanding | 1.81B |
| Shares Change (YoY) | +82.76% |
| Shares Change (QoQ) | +3.95% |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 7.30% |
| Float | 1.68B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.20 |
| P/TBV Ratio | 1.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.25 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.08 |
Financial Position
The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.00.
| Current Ratio | 2.88 |
| Quick Ratio | 2.70 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -8.56% and return on invested capital (ROIC) is -11.71%.
| Return on Equity (ROE) | -8.56% |
| Return on Assets (ROA) | -10.27% |
| Return on Invested Capital (ROIC) | -11.71% |
| Return on Capital Employed (ROCE) | -17.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -977,471 |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.33% in the last 52 weeks. The beta is -0.74, so Purple Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.74 |
| 52-Week Price Change | -78.33% |
| 50-Day Moving Average | 1.78 |
| 200-Day Moving Average | 4.06 |
| Relative Strength Index (RSI) | 42.18 |
| Average Volume (20 Days) | 10,777,552 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -208,897 |
| Operating Income | -19.51M |
| Pretax Income | -8.85M |
| Net Income | -8.80M |
| EBITDA | -19.41M |
| EBIT | -19.51M |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
The company has 19.94 million in cash and 347,038 in debt, giving a net cash position of 19.60 million or 0.01 per share.
| Cash & Cash Equivalents | 19.94M |
| Total Debt | 347,038 |
| Net Cash | 19.60M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 107.98M |
| Book Value Per Share | 0.20 |
| Working Capital | 13.89M |
Cash Flow
In the last 12 months, operating cash flow was -29.75 million and capital expenditures -6,739, giving a free cash flow of -29.76 million.
| Operating Cash Flow | -29.75M |
| Capital Expenditures | -6,739 |
| Free Cash Flow | -29.76M |
| FCF Per Share | -0.02 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Purple Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -82.76% |
| Shareholder Yield | -82.76% |
| Earnings Yield | -40.56% |
| FCF Yield | -137.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 6, 2019. It was a reverse split with a ratio of 0.05.
| Last Split Date | Jan 6, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |